OmniAb falls 11.6% after Analyst & Investor Day highlights partner pipeline and new platform

What happened

OmniAb (OABI) fell 11.6% on October 6, 2026, after its Analyst & Investor Day highlighted partners’ drug discovery pipelines and introduced the OmniTides™ platform. The decline followed presentations on the outlook for the xPloration® platform and partner programs, which Seeking Alpha and GuruFocus summarized. Zacks Investment Research also upgraded OmniAb to a Zacks Rank #2 (Buy), citing greater optimism about the company’s earnings prospects.

How big was the move

The stock closed at $4.35 after the decline, with trading volume 1.5 times its 20-day average. The drop was 1.9 times a typical daily move for this stock and was 9.8 percentage points worse than the healthcare sector median, which fell 1.8% on the day. The S&P 500 rose 0.6% on the session and rose 1.9% over the last five trading days, while OmniAb fell 8.2% over the same five-session span.

The technical picture

Technically, the stock sat 4.8% below its 20-day moving average but 9.5% above its 50-day average and 78.1% above its 200-day average. The 50-day average was above the 200-day average, a sign of an established uptrend, and the stock had traded above the 200-day average for 102 consecutive trading days. Its 14-day Relative Strength Index was 47, in a neutral range, while recent volatility ran at 97% annualized over 60 days, higher than 93% of its own readings over five years.

Over one month the stock rose 0.5%, over three months it rose 89.1%, and over one year it rose 166.9%, leaving it 150.4 percentage points ahead of the S&P 500 for that period. The shares remained 19.9% below their 52-week high, reflecting both rapid gains earlier in the year and the pullback on October 6.

Fundamentals and valuation

For the four quarters through June 30, 2026, OmniAb reported revenue of $38.4 million, a gain that grew 66.9% from a year earlier. Diluted earnings per share for the period was $-0.36, and gross margin narrowed to 50.5% from 98.9% a year earlier. Operating margin was 125.8% versus 307.1% a year earlier, while free-cash-flow margin stood at 47.2%.

The company reported net cash of $5.4 million on the balance sheet, and share count increased by 21.3% over one year. Market value was $706.0 million and the free-cash-flow yield was 2.6%, which leaves valuation mixed against the company’s growth profile.

Earnings and analyst expectations

OmniAb’s last report, on August 6, 2026, showed earnings per share of $-0.05 against $-0.12 expected, 58.3% above estimates. That marked two consecutive quarters beating estimates, and the average surprise over the last four reports was 14.5% above estimates. The typical two-day reaction after recent reports was that the stock rose 1.7%.

Nine analysts currently cover the stock and the consensus rating is Buy; 100% of ratings fall into the Buy category or higher. The consensus price target is $4.00, which is 8.0% below the closing price on October 6, 2026. The company’s next report is scheduled for November 3, 2026.

What to watch

• November 3, 2026: next earnings report date
• Consensus price target of $4.00, 8.0% below the closing price
• Trading volume relative to its 20-day average; on October 6 volume was 1.5 times its 20-day average
• Progress and partner updates related to the xPloration® platform and the new OmniTides™ platform
• Any further analyst revisions following the Analyst & Investor Day